Factive gemifloxacin mesylate: Completed Phase IV enrollment

OSCI completed enrollment of >7,500 patients in the U.S. Phase IV post-marketing FORCE trial

Read the full 140 word article

How to gain access

Continue reading with a
two-week free trial.